Six month repeat cognitive testing to identify people with MCI at greatest AD dementia risk
Systematic review. The authors reviewed the literature using traditional (e.g. PubMed) sources. There is a modest literature on change scores in the context of the AD clinical spectrum, but few investigations have evaluated whether short-term changes may be able to identify a high-risk subgroup of people with MCI. The authors have published a systematic review of this literature (Jutten et al. 2020) and appropriately refer to relevant citations here.Interpretation: Our findings suggest that short-term changes in cognition may be useful as part of a strategy to identify subsets of people with MCI who are at highest risk of conversion. Findings were clearest for memory and language. Domain-specific changes appeared to be independent from other biomarkers used to identify people at highest risk. Domain-specific changes did not appear to be better than changes in global cognition as measured by the MMSE or the CDR-sum of boxes.Future directions: Short-term changes in cognition may be useful to help identify a subgroup of people with MCI at highest risk of conversion to AD dementia. Future work could consider time frames shorter than the 6-month data we had available, better characterizing changes with more than 2 time points, or developing strategies that combine changes in cognition with other biomarkers to identify a subgroup of people with MCI to target for treatment.
Authors
- Douglas Tommet
- Melissa Lamar (ORCID: https://orcid.org/0000-0001-6130-5543)
- Roos J. Jutten (ORCID: https://orcid.org/0000-0002-3712-4790)
- Dan Mungas (ORCID: https://orcid.org/0000-0003-2035-7085)
- Evan Grandoit (ORCID: https://orcid.org/0000-0003-4926-6013)
- Richard N. Jones (ORCID: https://orcid.org/0000-0002-1049-218X)
- Connie Nakano
- Nancy S. Foldi (ORCID: https://orcid.org/0000-0001-8810-8558)
- Phoebe Scollard
- Chun Wang (ORCID: https://orcid.org/0000-0003-2634-4795)
- Seo-Eun Choi
- the Alzheimer's Disease Neuroimaging Initiative
- Laura E Gibbons
- Laura Rabin
- Paul K Crane
- Michael Lee
Institutions
- Queens College, CUNY (US)
- Northwestern University (US)
- Rush University Medical Center (US)
- University of Washington (US)
- Cornell University (US)
- Brown University (US)
- Massachusetts General Hospital (US)
- MIND Research Institute (US)
- University of Washington Applied Physics Laboratory (US)
- Brooklyn College (US)
- University of California, Davis (US)
Publication Details
- Journal
- medRxiv
- Published
- 2025-12-30
- DOI
- https://doi.org/10.64898/2025.12.30.25343228
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- U.S. Department of Defense
- Alzheimer's Association
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Biogen
- Meso Scale Diagnostics
- Alzheimer's Disease Neuroimaging Initiative
- BioClinica
- Novartis Pharmaceuticals Corporation
- Eisai
- H. Lundbeck A/S
- IXICO
- National Institutes of Health
- Genentech
- National Institute of General Medical Sciences